Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats

Drug Metabolism and Disposition

Volumn 36, Issue 12, 2008, Pages 2564-2570

  He, Kan ^a,c   Lago, Michael W ^b   Iyer, Ramaswamy A ^a   Shyu, Wen Chyi ^a   Humphreys, William G ^a   Christopher, Lisa J ^a  

^a Department of Pharmaceutical Candidate Optimization ^*  (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UniTris Biopharma Co   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DASATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; BREAST; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDICATION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG MILK LEVEL; FEMALE; FETUS; FETUS LIVER; ISOTOPE LABELING; KIDNEY; LIQUID CHROMATOGRAPHY; LUNG PARENCHYMA; MATERNAL BLOOD; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLACENTA; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; AREA UNDER CURVE; AUTORADIOGRAPHY; FEMALE; FETUS; MILK; MOLECULAR STRUCTURE; PREGNANCY; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLES; TISSUE DISTRIBUTION;

RATTUS;

EID: 57349096366     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022764     Document Type: Article

References (26)

1. 15N-labeled dasatinib and its piperazine N-dealkyl metabolite. J Label Compd Radiopharm 51:41-47.
2. Ando T, Kusuhara H, Merino G, Alvarez AI, Schinkel AH, and Sugiyama Y (2007) Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos 35:1873-1879.
3. Atkinson HC and Begg EJ (1990) Prediction of drug distribution into human milk from physicochemical characteristics. Clin Pharmacokinet 18:151-167.
4. Atkinson HC, Begg EJ, and Darlow BA (1988) Drugs in human milk. Clinical pharmacokinetic considerations. Clin Pharmacokinet 14:217-240.
5. 14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys. Drug Metab Dispos 36:1341-1356.
6. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, et al. (2008b) Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 36:1357-1364.
7. Daley GQ, Van Etten RA, and Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824-830.
8. Dorman DC, Allen SL, Byczkowski JZ, Claudio L, Fisher JE Jr, Fisher JW, Harry GJ, Li AA, Makris SL, Padilla S, et al. (2001) Methods to identify and characterize developmental neurotoxicity for human health risk assessment. III: Pharmacokinetic and pharmacodynamic considerations. Environ Health Perspect 109 (Suppl 1):101-111.
9. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, and Clark RE (2008) Effective dasatinib uptake may occur without human organic Cation Transporter 1 (hOCT1): implications for the treatment of imatinib resistant chronic myeloid leukaemia. Blood 112:3348-3354.
10. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, et al. (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109:4143-4150.
11. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, and Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800-807.
12. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, et al. (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303-2309.
13. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, and Schinkel AH (2005) The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11:127-129.
14. Kamath AV, Wang J, Lee FY, and Marathe PH (2008) Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 61:365-376.
15. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, et al. (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658-6661.
16. Lugo TG, Pendergast AM, Muller AJ, and Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079-1082.
17. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, and Schinkel AH (2005) The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 67:1758-1764.
18. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M, and Cortes J (2007) Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 109: 497-499.
19. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, and Heinrich MC (2006) Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66:473-481.
20. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, and Akin C (2006) Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108:286-291.
21. Solon EG and Kraus L (2001) Quantitative whole-body autoradiography in the pharmaceutical industry. Survey results on study design, methods, and regulatory compliance. J Pharmacol Toxicol Methods 46:73-81.
22. Syme MR, Paxton JW, and Keelan JA (2004) Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 43:487-514.
23. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-2541.
24. Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, et al. (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790-5797.
25. van Kalken CK, Giaccone G, van der Valk P, Kuiper CM, Hadisaputro MM, Bosma SA, Scheper RJ, Meijer CJ, and Pinedo HM (1992) Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am J Pathol 141:1063-1072.
26. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, and Brouwer KL (2006) The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 70:2127-2133.